PATENT CLAIM ANALYSIS

Application Number: 16068703
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-01
Patent Classification: ["514", "471000"]

Abstract:
This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.

Claim (Index 7):
The method of  claims 1  through  6  wherein said dosage is administered daily for at least about 10 days.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 99.0
- Lexical Diversity: 1.48
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14763750', '12134707', '15004218', '15869672', '15680417']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7322795081854443
- 35 USC 102 Novelty (BERT): 0.518550944567987
- Combined Prediction Score: 0.7109066518236986
- Mean Citation Score: 210.97209000000004
- Max Citation Score: 226.95691
- Similarity Product: 132.20134058663248

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test